BBI Brickell Biotech, Inc.

Brickell Biotech, Inc. engages in the development of prescription therapeutics for treatment of skin diseases. Its product pipeline includes potential novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

$2.35  +0.05 (2.17%)
As of 09/07/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1999
Outstanding shares:  2,873,965
Average volume:  76,354
Market cap:   $6,753,818
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -0.17
PB ratio:   17.54
PS ratio:   19.46
Return on equity:   -248.50%
Net income %:   -11,492.51%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy